Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 6/20 | 0.86 |
| ▸ | TUBB | P07437 | 6/20 | 0.86 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.86 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.86 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.86 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.86 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.86 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.86 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.86 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.86 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.86 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.86 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.86 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.86 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.86 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.86 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Casticin SCHEMBL30442880 | 1.00 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Casticin SCHEMBL29926095 | 1.00 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Chrysosplenol D SCHEMBL11133546 | 0.93 | ALOX5 (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Centaureidin SCHEMBL9953 | 0.93 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Chrysosplenol D SCHEMBL29359614 | 0.93 | ALOX5 (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10432667 | 0.93 | MKNK2 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Artemetin SCHEMBL2122576 | 0.91 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Artemetin SCHEMBL29550082 | 0.91 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30082745 | 0.91 | MEN1 (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Artemetin SCHEMBL29416756 | 0.91 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-118006548-B | Biological agent for treating knee arthritis | 超越再生医学(杭州)有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118006548-A | Biological agent for treating knee arthritis | 超越健康科技(浙江)有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20240099344-A1 | HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE | FIRMENICH SA (CH) | 2024-03-28 | — | — | US | claimed |
| US-20240026314-A1 | POLYPEPTIDES FOR USE IN THE SYNTHESIS OF BIOACTIVE PHENOLIC COMPOUNDS | ROTHSTEIN STEVEN (CA) | 2024-01-25 | — | — | US | claimed |
| CN-116999477-A | Preparation and application of herba Artemisiae Annuae sesquiterpene extract external preparation for treating inflammatory dermatoses | 首都医科大学 | 2023-11-07 | — | — | CN | claimed |
| EP-4258900-A1 | HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE | Firmenich SA (CH) | 2023-10-18 | — | — | EP | claimed |
| EP-4251758-A1 | POLYPEPTIDES FOR USE IN THE SYNTHESIS OF BIOACTIVE PHENOLIC COMPOUNDS | Rothstein, Steven (CA) | 2023-10-04 | — | — | EP | claimed |
| CN-116712493-A | Application of tendril Jing Zishui extract in preparation of migraine treatment medicine | 天津中医药大学 | 2023-09-08 | — | — | CN | claimed |
| CN-100560084-C | Method and preparation having antiallergic effect | DENOVASTELLA AB (SE) | 2009-11-18 | — | — | CN | claimed |
| WO-2009118338-A2 | USE OF A POLYPHENOLIC TYPE COMPOUND FOR PREVENTING OR TREATING A POLYGLUTAMINE EXPANSION NEURODEGENERATIVE DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-10-01 | — | — | WO | claimed |
| US-20080249164-A1 | Antimicrobial and Antinflammatory Composition | DENOVASTELLA AB (SE) | 2008-10-09 | — | — | US | claimed |
| US-20080160083-A1 | Delivering effective amounts of Chasteberry Extract, Pyridoxine, and Magnesium in a single dosage unit and a method of treating PMS and related disorders; oral dosage | NORTHERN HOLDINGS INC. | 2008-07-03 | — | — | US | claimed |
| EP-1898893-A1 | ANTIMICROBIAL AND ANTIINFLAMMATORY COMPOSITION | Denovastella AB (SE) | 2008-03-19 | — | — | EP | claimed |
| CN-101028261-A | Use of casticin in preparation of medicine against premenstrual syndrome | NO 2 MILITARY MEDICAL UNIV OF (CN) | 2007-09-05 | — | — | CN | claimed |
| EP-1776071-A2 | COATED VAGINAL DEVICES FOR VAGINAL DELIVERY OF THERAPEUTICALLY EFFECTIVE AND/ OR HEALTH-PROMOTING AGENTS | UMD, Inc. (US) | 2007-04-25 | — | — | EP | claimed |
| WO-2007004952-A1 | ANTIMICROBIAL AND ANTIINFLAMMATORY COMPOSITION | DENOVASTELLA AB (SE) | 2007-01-11 | — | — | WO | claimed |
| WO-2006017341-A2 | COATED VAGINAL DEVICES FOR VAGINAL DELIVERY OF THERAPEUTICALLY EFFECTIVE AND/ OR HEALTH-PROMOTING AGENTS | UMD, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20050276836-A1 | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents | UMD, INC. | 2005-12-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160083-A1 | Delivering effective amounts of Chasteberry Extract, Pyridoxine, and Magnesium in a single dosage unit and a method of treating PMS and related disorders; oral dosage | PNPO, PRDX5, PGR | TUBB4A 3561/4885TUBB 2629/4885TUBA3C 3464/4885 |
| US-20240026314-A1 | POLYPEPTIDES FOR USE IN THE SYNTHESIS OF BIOACTIVE PHENOLIC COMPOUNDS | COMT, PNMT, GNMT | TUBB4A 3257/4885TUBB 3882/4885TUBA3C 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.